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and provides a preclinical model for therapeutic interventions.
marrow.
1,16
However, large numbers of cells are required for successful
However, even following sublethal irradiation of SCID mice To determine the percentage of human hematopoietic cells in Ͼ70%.
the SCID mouse, bone marrow samples from mice that had been transplanted with UCB grafts were incubated with mouse monoclonal antibodies to human CD33, CD34, CD45
Preparation of CD34 + umbilical cord blood fractions and CD38. The initial leukemias and BM samples from mice that had been transplanted with leukemic grafts were stained UCB cells were incubated with an IgG2a antibody against or double-stained with the following mouse monoclonal anti-CD34 (MoAb 561) which was noncovalently linked to a ratbodies: CD34-FITC, CD34-PE, CD38-PE, CD34-FITC/IgG 1 -PE, anti-mouse IgG2a-conjugated immunomagnetic beads CD34-FITC/CD38-PE, CD34-FITC/HLA-DR-PE, CD34-FITC/c-(Dynabeads; Dynal, Oslo, Norway). CD34
+ cells were eluted kit-PE, CD34-FITC/CD33-PE and finally CD45-FITC/CD33-PE. from the beads using a polyclonal antibody preparation Mouse IgG 1 -FITC and mouse IgG 1 -PE conjugated antibodies directed against the Fab fragment of the CD34 antibody and samples from nontransplanted SCID mice were used as (Detachabead; Dynal). Systems). Erythrocytes and dead cells were excluded from weeks of age) were purchased (Harlan CPB, Austerlitz, The analysis by gating on forward and orthogonal light scatter. Netherlands). Nonobese diabetic SCID (NOD/SCID), specifiCells recovered from SCID mouse bone marrow (BM) with cally NOD/Lt-SCID/Sz mice (11 weeks of age), were obtained positive staining for two antibodies specific for human hemafrom Jackson Laboratories (Bar Harbour, MA, USA). Housing, topoietic cells were considered to be graft derived. Tissue-tek II (Miles Laboratories, Naperville, MI, USA), frozen St Louis, MO, USA) intraperitoneally, 5 days a week as and stored at −70°C. Cryostat sections of 5 m were prepared. described. 16 Mice transplanted with UCB did not receive Tissue fixation and immunoperoxidase staining of cryostat growth factor treatment.
sections were performed essentially as described by de Jong et al. 33 For fixation, a hexazotized pararosaniline solution (0.5 ml, 4%) was added to NaNO 2 (0.5 ml, 4%), diluted in Liposome preparation 165 ml sterile water and applied to dry tissue sections (2 min) followed by washing in PBS. 33 MAb binding was detected using a modified protocol involving NiSO 4 -supplemented Cl 2 MDP liposomes were prepared as reported. 30 Briefly, 75 mg phosphatidyl choline (Lipoid, Ludwigshafen, Germany) DAB and counterstaining of the nuclei with nuclear fast red.
34
Sections were incubated with a panel of monoclonal antiand 11 mg cholesterol (Sigma) were dissolved in chloroform in a round bottom flask. After low vacuum rotary evaporation bodies to determine the effect of TBI and TBI with macrophage depletion by Cl 2 MDP on macrophage subsets in the at 37°C the lipids were dispersed by gentle rotation in 10 ml PBS in which 2.5 mg clodronate (a gift of Boehringer spleen as representatives of phagocytic cells in direct contact with the blood stream. The antibodies used were F4/80 35, 36 Mannheim, Mannheim, Germany) was dissolved. The resulting liposomes were washed twice at 100 000 g for 30 (identifying especially red pulp macrophages), ER-HR3 37, 38 (major subset of red pulp macrophages) ER-TR9 39, 40 (marginal min to remove free, non-entrapped diphosphonate. The liposomes were then resuspended in 4 ml phosphate-buffered zone macrophages), MOMA-1 41 (marginal metallophilic macrophages), Monts-4 42 (marginal metallophilic and white saline (PBS) (liposome stock solution). SCID mice were injected in a lateral tail vein with 0.2 ml liposome stock solpulp macrophages) and N418 (anti-CD11c) 43 ,44 (dendritic (Table 1) . Leukemic day 4 after conditioning. Red pulp, white pulp and marginal zone macrophage populations identified by immunophenotumor load per mouse increased three-to 12-fold (Table 1) . Graft failure was defined as less than 0.5% of AML cells in typic analysis had not changed significantly (Table 4 ). In contrast, dendritic cells (identified by the monoclonal antibodies the SCID mouse BM. Among the 25 mice transplanted with AML cells following liposome treatment no graft failures were observed, whereas six graft failures were seen in control Table 2 Cell dose titration of AML2 in SCID mice with and withrecipients (P = 0.02, Fisher's exact test) ( Table 1) The outgrowth of graded cell doses of AML2 in SCID mice Macrophage depletion enhances outgrowth of UCB additional conditioning with Cl 2 MDP liposomes (Table 3) .
BM, bone marrow; MD, macrophage depletion by pretreatment with Cl 2 MDP liposomes; TBI, total body irradiation.
Cell dose titrations with CD34
+ selected UCB cells were per- Table 3 Cell dose titration of two umbilical cord blood samples N418 and ER-BMDM1) had disappeared from the red pulp in SCID mice with and without Cl2MDP pretreatment and from the white pulp as a consequence of the sublethal dose of TBI alone. Combined treatment with TBI and Cl 2 MDP
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liposomes depleted all identifiable macrophages from the white pulp, the red pulp and the marginal zone ( The injection of 0.2 ml of Cl 2 MDP liposomes on the day bone marrow. This treatment is easy to apply and without significant toxicity. Outgrowth of primary human AML increased two-to 10-fold and engraftment of umbilical cord blood cells was achieved with at least 10-fold smaller grafts (Tables 1 and  3 ). Probabilities of graft failure were significantly reduced (Table 1) . Thus, conditioning with TBI and Cl 2 MDP liposomes in combination permits the establishment of relatively small human hematopoietic cell grafts, eg 1 × 10 6 unseparated UCB were evaluated on days 4 and 45 after TBI, and compared to NOD/SCID mice have multiple immunological defects. In untreated SCID mouse controls. The data obtained with these antiaddition to B and T cell deficiency, NK function is absent and bodies were similar to data obtained with the use of independent these mice may also have a macrophage maturation defect.
49
antibodies BM-8, SER-4, and ER-BMDM1 (data not shown). Two or three mice per group were evaluated.
It has been shown that the tumor load in the spleen of TBI, total body irradiation; MD, macrophage depletion by pretreat-SCID/NOD mice transplanted with human CEM T lymphoment with Cl 2 MDP liposomes; wp, white pulp; rp, red pulp; pwp, blasts was increased four-fold as compared to similarly transperipheral white pulp; mz, marginal zone. The number of macroplanted SCID mice. 49 Our results indicate that the outgrowth phages staining with a specific antibody within these anatomically of AML and UCB grafts in irradiated SCID mice conditioned defined regions were scored semiquantitatively: 4+, Ͼ50%
with additional Cl 2 MDP liposomes may be as effective as that positivity-confluent; 3+, 50%; 2+, 10-50%; 1+, scarce; *, only remnants.
in sublethally irradiated NOD/SCID mice. 
